Rates of overdose, mental health crises increased after dose tapering among patients prescribed stable, long-term, higher-dose opioid therapy
Money to be used by communities for addiction treatment, prevention services, and other significant costs associated with the epidemic
High-dose buprenorphine protocol well tolerated in patients with untreated opioid use disorder; no reports of respiratory depression or sedation
There are still considerable gaps in medication care, with Black enrollees having lower use than Whites
However, opioids still commonly dispensed, with high-risk prescribing practices suspected in young children
Less than 5 percent of prescribers account for half of all buprenorphine treatment in the country
Improvement seen in treatment satisfaction and several secondary end points for depot buprenorphine versus sublingual buprenorphine
Differences between the two trajectories persist in opioid fills, misuse beyond 12 months
8-mg dose of naloxone hydrochloride nasal spray now approved with 2-mg and 4-mg doses